Virological Response Study of the HCV Vaccine IC41

Inclusion Criteria: * Written informed consent obtained prior to study entry * Patients with chronic hepatitis C; genotype 1 * Treatment naive patients * Male and Female, 18 to 55 years * Presence of HLA-A2 marker * Mentally healthy * No clinically relevant pathological findings in any of the investigations at screening * Treatment naive patients with chronic Hepatitis C of genotype 1 Exclusion Criteria: * Positive results in HIV, HBsAg and HAV-Ag (IgM) * Other causes of chronic hepatitis * History of autoimmune diseases * Previous vaccination with any prophylactic or therapeutic Hepatitis C vaccine (in a clinical study) * Active or passive vaccination 4 weeks before and during the entire study period * Decompensated liver disease * History of severe hypersensitivity reactions and anaphylaxis * Known allergic reactions to one of the components of the vaccine and Imiquimod cream * Clinically significant diseases which, in the opinion of the Investigator, might lead to frequent hospitalization/medical attendance * Malignancies * Immunosuppressive therapy * Pregnancy, lactation or breast-feeding * Unwillingness to practice appropriate contraception * Participation in another study with an investigational drug within 1 month prior to enrolment and the entire study period * Patients, who in the opinion of the Investigator, might not be able to comply with the study protocol (e.g.: Drug addiction, alcoholism)